References

1. 1.
   Chinese Rheumatology Association.2016 China gout clinical practice guideline［J］.Chin J Intern Med， 2016，55（11）：892-899.
2. 2.
   SHU J， LI F， QIN Y.Research progress of pathology of gout and clinical treatment with traditional Chinese and western medicine［J］.Chin J Exp Tradit Med Form，2020，26（2）：218-227.
3. 3.
   DENG S H，DANG W T，LIU J，et al.Differential diagnosis of acute and chronic gouty arthritis by multijoint ultrasound［J］.Ultrasound Med Biol，2021，47（10）：2853-2859.
4. 4.
   GRASSI W，DE ANGELIS R.Clinical features of gout［J］. Reumatismo，2012，63（4）：238-245.
5. 5.
   FERGUSON L D，MOLENBERGHS G，VERBEKE G，et al. Gout and incidence of 12 cardiovascular diseases：A case-control study including 152 663 individuals with gout and 709 981 matched controls［J］.Lancet Rheumatol，2024，6（3）：e156-e167.
6. 6.
   DEHLIN M，JACOBSSON L，RODDY E.Global epidemiology of gout：Prevalence，incidence，treatment patterns and risk factors［J］.Nat Rev Rheumatol，2020，16（7）：380-390.
7. 7.
   SINGH J A，GAFFO A.Gout epidemiology and comorbidities［J］.Semin Arthritis Rheum，2020，50（3S）：S11-S16.
8. 8.
   YANG X，ZHANG H，YAN W，et al.A retrospective study of 2 087 patients with gout co-morbidity and complications［J］.J Yunnan Univ Chin Med，2021，44（5）：19-24.
9. 9.
   RODDY E，BAJPAI R，FORRESTER H，et al.Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout：Propensity score-matched cohort studies in the UK clinical practice research datalink［J］.Ann Rheum Dis，2023，82（12）：1618-1625.
10. 10.
    BAI Y，WU B，GOU L，et al.Cardiovascular safety evaluation of febuxostat and allopurinol：Findings from the FDA adverse event reporting system［J］. J Clin Med，2023，12（18）：6089.
11. 11.
    STAMP L K，DALBETH N.What is allopurinol failure and what should we do about it？［J］.J Rheumatol，2024，jrheum.2024-0144.
12. 12.
    SIM B L，SIM B Z，TUNBRIDGE M，et al.Examining the characteristics of colchicine-induced myelosuppression in clinical cases：A systematic review［J］.J Rheumatol，2023，50（3）：400-407.
13. 13.
    ZHANG X，ZENG H，LI H，et al.Pathogenesis of gouty arthritis and intervention with Chinese medicines：A review［J］.Chin J Exp Tradit Med Form，2022，28（11）：256-267.
14. 14.
    ZHANG Y，YANG J，LI X.TCM syndrome types and pathogenic characteristics of gout patients［J］.Clin Res Practice，2018，3（36）：136-138.
15. 15.
    QIU X，CHEN C，LI X，et al.Distribution characteristics of TCM syndromes of gouty arthritis and analysis of the rules of drug use［J］.J Yunnan Univ Chin Med，2019，42（5）：81-85.
16. 16.
    CAO Y，XIE K，MA W，et al.Research on the correlation between pro-inflammatory cytokines in gouty arthritis and traditional Chinese medicine syndromes［J］.J Guizhou Univ Tradit Chin Med，2018，40（1）：55-59.
17. 17.
    Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China： Volume 1［M］.Beijing：China Medical Science Press，2020.
18. 18.
    ZHONG G，YANG B.Traditional Chinese pharmacy［M］.Beijing：China Press of Traditional Chinese Medicine，2021：272-273.
19. 19.
    JIANG Q.Practical rheumatological immunology of traditional Chinese medicine［M］.Beijing：China Press of Traditional Chinese Medicine，2022：138.
20. 20.
    ZHU W，GU D，JIANG T，et al.Turbid dampness Bi——the exploration of the traditional Chinese medicine name for gout［J］.J Tradit Chin Med，2011，52（17）：1521-1522.
21. 21.
    SHI R.The experience of professor LU Zhizheng in treating tongfneg Bi［J］.Hebei J Tradit Chin Med，2011，33（7）：965-966.
22. 22.
    National Administration of Traditional Chinese Medicine. ZY/T 001.1-001.9-94 diagnostic and therapeutic criteria for traditional Chinese medicine syndromes［S］.Nanjing：Nanjing University Press，1994：56.
23. 23.
    DI P，WANG X，ZHU W，et al.Investigation and analysis of TCM syndromes of 1 017 cases of gout［J］.Rheumatism Arthritis，2022，11（5）：21-25，36.
24. 24.
    RICHETTE P，DOHERTY M，PASCUAL E，et al.2018 updated European league against rheumatism evidence-based recommendations for the diagnosis of gout［J］.Ann Rheum Dis，2020，79（1）：31-38.
25. 25.
    ZHU W，ZHANG A，GU D，et al.Exploration of the distribution regularity of TCM syndrome in gouty arthritis［J］.J Tradit Chin Med，2012，53（19）：1667-1670.
26. 26.
    LIU J，XIE K，CAO Y，et al.The expression of TLRs/MyD88 in patients with acute gouty arthritis and its relationship with TCM syndrome pattern［J］.Rheumatism Arthritis，2018，7（3）：23-27，53.
27. 27.
    JIN F，LI H，KAN L，et al.Visual analysis on literature about TCM external treatment of gouty arthritis［J］.Chin J Libr Inf Sci Tradit Chin Med，2024，48（1）：158-163.
28. 28.
    XIE X，LI G，LIU Y，et al.A Meta-analysis of the effects of the Simiao decoction on the damp-heat agglutinated syndrome acute gouty arthritis［J］.Clin J Chin Med，2022，14（7）：130-134.
29. 29.
    LI J，ZHAO Q，QIN W，et al.Research progress on modern clinical application and mechanism of Simiao pill［J］.Chin Arch Tradit Chin Med，2023，41（10）：5-9.
30. 30.
    FANG J，LIU M，HUANG Z，et al.Efficacy and safety of Chinese medicinal prescriptions in treatment of acute gouty arthritis：A network Meta-analysis［J］.Chin J Exp Tradit Med Form，2023，29（12）：175-184.
31. 31.
    WANG W，HUANG S， WANG J.On the mechanism and clinical application of Ersi Bixie Tang in treating acute gouty arthritis［J］.Rheumatism Arthritis，2022，11（11）：55-59.
32. 32.
    ZHOU L，ZHAO W，MENG X.Clinical observation of gout prescription for the treatment of acute gout arthritis with damp-heat accumulation syndrome［J］.J Guangzhou Univ Tradit Chin Med，2023，40（6）：1394-1398.